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Objectives To study the serotype distributions of group B streptococci (GBS) isolated from blood and
cerebrospinal fluid and from the genital tract of pregnant women and to investigate any possible relation
between serotype, age and clinical manifestation.
Methods Invasive strains were collected from 1988 to 1997 and genital strains from 1995 to 1996. Strains of
GBS were serotyped with coagglutination. Clinical data were obtained from hospital notes.
Results A total of 144 invasive strains, 78 from neonates and infants and 66 from adults, were serotyped. The
most common isolates from neonates and infants were types III (62%), Ia (18%), and V (9%). The most common
isolates from adults were types III (29%), Ib (23%), V (21%) and II (15%). A majority of the adults (94%) had
an underlying medical condition. The most common serotypes of the 114 strains isolated from the genital tract
of pregnant women were types III (32%), V (22%), Ia (13%), Ib (13%) and II (11%).
Conclusions Serotype III was the single most frequent GBS isolate from infants and adults. Serotype V, which
appeared first in 1992, was the third most frequent isolate. A vaccine containing five GBS capsular
polysaccharides appears to be appropriate for the Swedish population.
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INTRODUCTION
The group B streptococcus (GBS) is a leading cause of invasive
neonatal infections and of infections in pregnant women [1–3].
The organism has also been recognized as a pathogen in adults
with severe underlying diseases [1,4–6]. The high morbidity
and mortality in invasive GBS infections justify research in
methods of prevention, for example, in the form of intrapartum
antimicrobial prophylaxis or vaccines. Based on the com-
position of the capsular polysaccharide (CPS), GBS can be
divided into at least nine different serogroups. Serum antibodies
against the CPSs provide type-specific protection against invas-
ive GBS infections [7–10]. Knowledge of the serotype dis-
tribution of invasive isolates is a prerequisite for vaccine
research. Since the serotype distribution might differ over time
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and between different populations continuous surveys are
necessary in many parts of the world.
The aim of the present study was to make a survey of the
serotype distribution of GBS isolates from the blood and cer-
ebrospinal fluid (CSF) in a Swedish population and to see if the
serotype distribution differed in different age-groups and in
patients with different clinical manifestations.
MATERIALS AND METHODS
Laboratory-based surveillance
Group B streptococcal isolates from normally sterile sites (blood,
CSF and synovial fluid) were saved from 1988 to 1997 at
the Department of Clinical Bacteriology, Sahlgrenska Hospital,
Go¨teborg (n = 84) and from 1995 also at the Departments of
Clinical Bacteriology, O¨stra Hospital, Go¨teborg (n = 14),
Halmstad Hospital (n = 23), Karlstad Hospital (n = 15) and Bora˚s
Hospital (n = 8) in Western Sweden. Invasive isolates were
identified as GBS by colony morphology, microscopy of Gram-
stained smears and coagglutination with group specific reagents
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(Streptex®; Murex Biotech Ltd, Dartfort, England). The strains
were stored in nutrient broth with horse serum and glucose at
70°C until serotyping was performed. Isolates from the cervix
of healthy pregnant women who attended Maternity Clinics
for routine care were collected in 1995 and 1996. The cervical
secretions were cultured directly on blood-agar and also after
24 h enrichment in Todd–Hewitt broth. Identification was
performed as described above. After subculture on blood-agar
these strains were stored in broth at 20°C until serotyping
was performed. Only one isolate from each infectious episode
was included in the study.
Serotyping
GBS isolates were serotyped by coagglutination (DAKO Group
B Streptococcus Serotyping Test, DAKO®) (Dakopatts AB,
A¨lvsjo, Sweden) [11] with type specific antisera for serotypes
Ia, Ib, II, III, IV and V. The accuracy of the test was confirmed
using reference strains for serotypes Ia, Ib, II, III, IV and V
(Culture Collection, University of Go¨teborg, CCUG 29779–
84). Strains that were not typable by coagglutination (11 invas-
ive strains and 11 carrier strains) were serotyped with pre-
cipitation techniques (ring test and diffusion test) [12,13] for
types I through VIII by Dr Jitka Motlova´, National Strep-
tococcus and Enterococcus Reference Laboratory, National
Institute of Public Health, Prague, the Czech Republic.
Clinical data
Clinical data (age, sex, gestational age, underlying medical con-
ditions, clinical manifestations and outcome) were obtained
from individual hospital notes. All hospital notes were found
and the relevant information was available for all patients.
Ethics
The study was approved by the Ethics Committee of Go¨teborg
University.
Statistical analysis
Serotype distributions between adult, early onset and genital
isolates were compared with the chi-squared test (2  7 tables).
Comparisons of the proportions of serotype III in late-onset
versus early onset and sepsis versus meningitis were carried out
using Fisher’s exact test with two-tailed P-values.
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RESULTS
A total of 144 invasive and 114 genital strains were serotyped.
Serotype distributions are shown in Table 1. Seventy-eight of
144 invasive strains (54%) were obtained from neonates and
infants and 66 (46%) from adults. No patient with invasive GBS
infection was found in the age-group 6 months to 23 years. No
differences of importance were found between the different
hospitals.
Neonates and infants
Serotype III was the most common serotype (62%) in neonates
and infants followed by serotype Ia (18%). In comparison with
this, all other serotypes were uncommon (3–9%). There were
no major differences in serotype distribution over time except
that the first case of serotype V did not appear until 1993.
Serotype V accounted for 12% of the strains from 1993 onwards.
Of the 78 neonates and infants (40 males, 38 females) with
invasive GBS infection, 64 had early onset disease (onset within
7 days after birth) and of those, 55 had onset of symptoms
within 24 h after birth. There were no differences in serotype
distribution between those with onset within 24 h and those
with onset 1–6 days after birth. Of the 14 infants with late-
onset disease (onset between 7 days and 6 months after birth),
13 (93%) were infected with serotype III compared to 35 of 64
(55%) with early onset disease (P = 0.007, Fisher’s exact test)
but the overall comparison of all serotypes (x2, 2  7 table) was
not significant (P = 0.29). All eight strains from infants with
meningitis were serotype III compared with 40 of 70 strains
from infants with sepsis without meningitis (P = 0.02, Fisher’s
exact test) but the overall comparison of all serotypes (x2, 2  7
table) was not significant (P = 0.29). Twenty neonates were
preterm (gestational age 37 weeks). The serotype distribution
from these infants was similar to the distribution seen in full-
term neonates. Two infants died (3%). They were both preterm
and were infected with serotypes Ia and Ib. Severe neurological
sequelae were seen in four infants infected with serotypes Ia
(n = 1), Ib (n = 1) and III (n = 2).
Genital isolates
There was a difference in the serotype distribution of isolates
from pregnant women and invasive isolates from early onset
infections in neonates (P = 0.009) and serotypes Ib, III and V
contributed most to this difference. Since all strains were col-
lected in 1995–96 differences over time could not be studied.
Adults
Sixty-six episodes of GBS infection were identified in 63 adults.
The mean and median ages for the 66 adults (36 males, 30
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Table 1 Serotype
distribution
[numbers (%)] of group B
streptococcus isolates from
blood and cerebrospinal
fluid (CSF) and
from the genital tract of
healthy, pregnant
women
Blood and CSF isolates
Neonates and infants
Serotype Early onset Late onset Adults Genital isolates
Ia 13 (20) 1 (7) 4 (6) 15 (13)
Ib 2 (3) 0 15 (23) 15 (13)
II 4 (6) 0 10 (15) 13 (11)
III 35 (55) 13 (93) 19 (29) 36 (32)
IV 2 (3) 0 1 (2) 3 (3)
V 7 (11) 0 14 (21) 25 (22)
Nontypeable 1 (1) 0 3 (5) 7 (6)
Total 64 14 66 114
females) were 62 and 67 years, respectively (range 24–92 years).
The serotype distribution related to clinical manifestations is
shown in Table 2. Fifty-nine of 63 patients had a known under-
lying medical condition, the most common being malignant
disease (n = 18), renal disease (n = 10), chronic heart failure
(n = 8), recent operation (n = 6), skull trauma (n = 4), pregnancy
(n = 2). Eleven patients had diabetes mellitus and seven of those
also had another risk factor. Three patients had two infectious
episodes with intervals between 45 days and 8 months. The
recurrent infections were caused by the same serotypes as the
initial infections in all three patients (serotypes Ia, II and III)
and the manifestations were erysipelas, arthritis and sep-
sis/endocarditis. Six patients (9%) died during or soon after the
infection (serotypes: Ib = 2, II = 2, III = 1 and V = 1).
Serotype III was the most common serotype among invasive
strains from adults. Serotypes Ib, II and V were approximately
equally common among isolates from adults (15–23%), whereas
serotype Ia was uncommon (6%). There were no differences
over time except that the first infection with serotype V
occurred in 1992. Serotype V accounted for 23% of the strains
from 1992. There was no significant difference between invas-
ive isolates from adults and genital isolates. A significant dif-
ference in the serodistribution between adults and neonates
Table 2 Serotype
distribution of
group B streptococcus
isolates from blood
and cerebrospinal fluid
related to clinical
manifestation in adults
Manifestation Ia Ib II III IV V Nontypeable
Sepsis, unknown focus 2 8 3 9 6 1
Erysipelas 2 1 2 1 1 3 1
Arthritis 1 4 1 2
Meningitis 3 2
Endocarditis 1 1 3
Others 1 3 3 1
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(P  0.0001) was found and serotypes Ia, Ib and III contributed
the most to this.
DISCUSSION
The present study from Sweden shows that serotypes Ia, Ib, II,
III, IV and V are represented among invasive GBS isolates from
neonates and infants. Type III was by far the most common
serotype followed by serotypes Ia and V. The results indicate
that type V increased during the study period. Several studies
of the GBS serotype distribution have been performed in North
America. In most of these studies, type III has been the most
common serotype [4,14], but in some recent studies type Ia
was as common as or more common than type III [15–17].
Several North American studies have clearly shown that sero-
type V has increased from being almost nonexistent to one
of the most common serotypes during the 1990s [15–17]. A
European study from the early 1990s showed that serotypes III,
Ia and Ib dominated and the proportion of type V was 5% [18].
As many studies have not reported early and late-onset infec-
tions separately and because late-onset infections are less com-
mon it is difficult to make detailed comparisons about
differences in serotype distribution. Our study shows in
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agreement with other studies [14–17] that serotype III is even
more dominant in late-onset than in early onset infections.
Since GBS strains causing early-onset disease in neonates are
acquired in the birth canal, it is to be expected that the serotype
distribution of isolates from early-onset infections would be
similar to the distribution among isolates from the female genital
tract. This was also the case in North American studies which
found almost identical serotype distributions among neonatal
blood isolates and isolates from pregnant women [14,19]. In
contrast, the present study showed a more even distribution of
serotypes in the female genital tract than in early-onset infec-
tions. The strains from the female genital tract were, however,
collected only during 1995–96 and do not represent the colon-
ization during the entire period of collection of invasive strains.
We found that serotypes III (32%) and V (22%) were most
common. A recent study from Japan has shown that serotypes
VIII (36%) and VI (25%) were the most common types in
healthy pregnant women [20].
There was a significant difference in the distribution of sero-
types in adults in comparison with infants in the present study.
Even though serotype III was the most common serotype in
both groups its dominance was less pronounced in the adults.
Serotype V seems to have emerged as a ‘new strain’ also in
adults and accounted for 21% in the present study. In a study
from Norway and England covering the years 1990–93 serotype
V was found in only 3% of 155 adult cases [18]. Recent studies
from the US have a similar frequency of serotype V as in the
present study but a higher frequency of serotype Ia and a lower
frequency of serotype III [15,17].
The most promising way to prevent neonatal GBS infection
is vaccination of women of childbearing age. A serotype III
conjugate vaccine has been given in a phase 2 study [21]. Such
a vaccine would provide coverage against 62% of neonatal and
infant infections (55% of early onset and 93% of late-onset
infections) in the population studied here. A recent study has
shown immunogenicity of a conjugate vaccine for serotypes Ia
and Ib [22]. To reach coverage of more than 90% a pentavalent
conjugated GBS polysaccharide vaccine consisting of serotypes
Ia, Ib, II, III and V would be needed.
If an effective vaccine against invasive GBS infections
becomes available for women of fertile age, with the aim of
preventing neonatal infections, it might also be considered for
immunocompromised individuals on the same indications as
the pneumococcal polysaccharide vaccine. To be used on this
indication it is important that it contains all of the five serotypes,
which most commonly cause disease in adults; Ia, Ib, II, III and
V.
According to North American studies, almost all adults with
invasive GBS infections have underlying medical conditions
known to predispose to infections [23,24]. The present study
shows that GBS is an important pathogen of adults with under-
lying medical conditions in a European country. Underlying
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medical conditions were seen in 94% of the adults and were
similar to the wide variety of risk factors seen in invasive pneu-
mococcal infections [25]. Recurrent GBS infections, found in
three adults in the present study, have been described previously
[26]. In contrast to other studies few infections (3%) were
associated with pregnancy [1,6,15]. This does not necessarily
mean that GBS infections are uncommon in pregnant women
in Western Sweden but may reflect that blood cultures are not
always performed in febrile, pregnant women.
In conclusion, invasive GBS infections in neonates and adults
can be caused by all serotypes from I to V. Serotype III is the
most common in all age groups. A GBS vaccine should include
five serotypes but its composition would need continuous re-
evaluation due to variations in serotype distribution over time.
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